Published in J Clin Oncol on December 12, 2011
Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. J Hematol Oncol (2014) 1.49
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood (2015) 1.21
Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol (2013) 1.06
Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma (2015) 0.98
No familial aggregation in chronic myeloid leukemia. Blood (2013) 0.92
Preleukemia: One name, many meanings. Leukemia (2016) 0.75
Association of Cancer Incidence and Duration of Residence in Geothermal Heating Area in Iceland: An Extended Follow-Up. PLoS One (2016) 0.75
A Fatal Case of Acute Myeloid Leukaemia-Methotrexate Related or Primary Autoimmune Disease Related: A Rare Case Report. J Clin Diagn Res (2016) 0.75
Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol (2008) 3.74
Acute myeloid leukemia: epidemiology and etiology. Cancer (2006) 2.82
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol (2011) 2.11
Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer (2009) 1.89
Familiality of cancer in Utah. Cancer Res (1994) 1.80
A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer (2005) 1.67
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood (2008) 1.65
High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood (2009) 1.65
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood (2008) 1.61
Familial aggregation of Hodgkin lymphoma and related tumors. Cancer (2004) 1.60
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica (2009) 1.50
Molecular genetics in acute myeloid leukemia. Curr Opin Oncol (2010) 1.33
Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data. Ann Hum Genet (2004) 1.28
Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica (2010) 1.25
Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol (2008) 1.19
Highly increased familial risks for specific lymphoma subtypes. Br J Haematol (2009) 1.16
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer (2009) 1.12
Familial leukaemia: a study of 909 families. Scand J Haematol (1975) 1.11
Benzene, the exposome and future investigations of leukemia etiology. Chem Biol Interact (2011) 1.01
A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation? Leukemia (2009) 0.97
Diet, lifestyle, and acute myeloid leukemia in the NIH-AARP cohort. Am J Epidemiol (2009) 0.94
Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics (2000) 0.92
Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia. Leuk Lymphoma (2009) 0.90
Etiology of acute myeloid leukemia in the elderly. Semin Hematol (2006) 0.87
Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol (2007) 3.32
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA (2007) 2.51
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol (2011) 2.34
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer (2007) 2.16
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol (2011) 2.11
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol (2007) 2.02
Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. Clin Infect Dis (2012) 2.01
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst (2009) 1.92
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (2008) 1.78
Minimal residual disease: what are the minimum requirements? J Clin Oncol (2014) 1.76
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica (2006) 1.63
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood (2008) 1.61
The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica (2006) 1.59
Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev (2008) 1.59
Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol (2007) 1.54
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol (2011) 1.51
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma (2011) 1.50
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica (2009) 1.50
Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum (2008) 1.50
Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr (2010) 1.47
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol (2012) 1.46
Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma (2014) 1.43
CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res (2008) 1.42
Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia? Leuk Lymphoma (2009) 1.41
Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. Int J Cancer (2012) 1.39
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). Leuk Lymphoma (2012) 1.38
Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology (2008) 1.36
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 1.33
Autoimmunity and lymphomagenesis. Int J Cancer (2009) 1.29
The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology (2009) 1.29
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood (2013) 1.27
FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. J Pathol (2009) 1.27
Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer (2010) 1.25
Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica (2010) 1.25
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst (2010) 1.24
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica (2009) 1.21
The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res (2002) 1.21
Myeloma and second primary cancers. N Engl J Med (2011) 1.20
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 1.19
Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res (2003) 1.18
Highly increased familial risks for specific lymphoma subtypes. Br J Haematol (2009) 1.16
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood (2009) 1.15
Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch Intern Med (2008) 1.14
Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica (2013) 1.14